Dermatological Drugs Market Forecast 2017-2027

LONDON, July 25, 2017 /PRNewswire/ --

Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma.

The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you:  

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 295-page report you will receive 111 tables and 92 figures - all unavailable elsewhere.

The 295-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope:  

• Dermatological drugs market forecasts from 2017-2027.

• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

• Analysis of the Psoriasis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx

• Analysis of the Skin Infections drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban

• Analysis of the Acne drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx

• Analysis of the Dermatitis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• Brazil
• Russia
• India
• Rest of World

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.

• Two interviews conducted by Visiongain with experts in the dermatological drugs market:
• Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation.
• Interview with Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma.

• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• Galderma (Nestle Skin Health S.A.)
• Johnson & Johnson
• AbbVie
• GlaxoSmithKline (GSK)
• Pfizer
• LEO Pharma

Our new report discusses issues and events affecting the dermatological drugs market:
• Highly fragmented and competitive market with significant variations in different geographic regions.
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities.
• Future paradigm-shifting pipeline products.
• Patent expirations.
• Launches of new drug categories.
• Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance.

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1929/Dermatological-Drugs-Market-Forecast-2017-2027

Companies and Organizations Mentioned in the Report:  

Abbott

AbbVie

Actavis

AET BioTech

Alkem Laboratories

Allergan

Almirall

Amgen

Anacor

Ascend Therapeutics

Astellas

Aurovindo

Barr Labs

Bayer

Betta Pharmaceuticals

Biocon/Mylan

Biofrontera

Biogen

Biovail Laboratories

BioXpress Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Brazilian Society of Dermatology

Cadila Healthcare

Can-Fite BioPharma

Cassiopea SpA

Celgene

Celltrion

Cempra

Cipher Pharmaceuticals

Cipla

Cubist Pharmaceuticals

Cutanea Life Sciences

Dow Pharmaceuticals Science

Dr Reddy's

Durata Therapeutics

Eisai

Eli Lilly

European Medicines Agency (EMA)

European Pharmaceutical Market Research Association (EPhMRA)

Food and Drug Association (FDA)

Foamix

Fougera

Fujifilm

G&E Herbal Biotechnology

Galderma

GlaxoSmithKline

Glenmark Pharmaceuticals

Heritage

Impax

Incyte

Janssen Biotech

Johnson & Johnson

Kyowa Hakko Kirin

L'Oreal

LEO Pharma

Lupin

Maruho

Mayne Pharma

Medicis

Medison Pharma

Melinta Pharmaceuticals

Merck

Merz Pharmaceuticals

Mitsubishi Tanabe

MorphoSys

Mylan

NanoBio Corporation

National Psoriasis Foundation (NPF)

NeoStrata Compnay Inc

Nestle Skin Health

Novan

Novartis

Perriogo

Pfizer

PharmaPraxis

Photocure

Pierre Fabre

Provectus Biopharmaceuticals

QLT Inc

Ranbaxy

Regeneron Pharmaceuticals

Roche

Samsung Bioepis

Samsung BioLogics

Sandoz

Sanofi

Schering-Plough

Shanghai CP Buojian Pharmaceutical

Sidmak Labs

Sol-Gel Technologies Ltd

Sun Pharma

Sunovion

Takeda

Tanabe

Tanja Todberg

Taro Pharmaceuticals

Teva

Thesan Pharmaceuticals Inc

Topica Pharmaceuticals

UCB

Valeant

Vical

Warner Chilcott

Watson Pharmaceuticals

Xenon Pharmaceuticals

Zydus

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com